Analysts Anticipate Greenbrook TMS Inc. (NASDAQ: GBNH) Will Announce Quarterly Sales of $ 11.70 Million

Equities research analysts expect Greenbrook TMS Inc. (NASDAQ: GBNH – Get Rating) to announce $ 11.70 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Greenbrook TMS’s earnings, with the lowest sales estimate coming in at $ 10.70 million and the highest estimate coming in at $ 12.70 million. Greenbrook TMS posted sales of $ 11.31 million in the same quarter last year, which suggests a positive year over year growth rate of 3.4%. The company is scheduled to issue its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Greenbrook TMS will report full-year sales of $ 60.00 million for the current fiscal year, with estimates ranging from $ 57.30 million to $ 62.70 million. For the next financial year, analysts anticipate that the business will report sales of $ 67.90 million, with estimates ranging from $ 63.40 million to $ 72.40 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that cover Greenbrook TMS.

Greenbrook TMS (NASDAQ: GBNH – Get Rating) last released its quarterly earnings results on Wednesday, March 30th. The company reported ($ 0.34) EPS for the quarter, topping the consensus estimate of ($ 0.38) by $ 0.04. Greenbrook TMS had a negative return on equity of 189.28% and a negative net margin of 47.42%. During the same period last year, the company earned ($ 0.60) earnings per share.

GBNH has been the topic of a number of research analyst reports. Zacks Investment Research lowered shares of Greenbrook TMS from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. Clarus Securities lowered their price target on shares of Greenbrook TMS from C $ 8.25 to C $ 7.50 in a report on Monday, April 4th. Canaccord Genuity Group downgraded shares of Greenbrook TMS to a “buy” rating in a research report on Monday, February 7th. Finally, Bloom Burton reiterated a “buy” rating on shares of Greenbrook TMS in a research report on Monday, April 4th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Based on data from, the stock has an average rating of “Buy” and a consensus target price of $ 14.32.

Hedge funds have recently added to or reduced their stakes in the business. Royce & Associates LP raised its holdings in Greenbrook TMS by 8.0% in the 4th quarter. Royce & Associates LP now owns 223,500 shares of the company’s stock valued at $ 977,000 after acquiring an additional 16,598 shares during the last quarter. Rockefeller Capital Management LP purchased a new stake in shares of Greenbrook TMS in the 3rd quarter valued at approximately $ 109,000. AdvisorShares Investments LLC grew its stake in shares of Greenbrook TMS by 365.5% in the 4th quarter. AdvisorShares Investments LLC now owns 64,214 shares of the company’s stock valued at $ 281,000 after buying an additional 50,418 shares during the period. Masters Capital Management LLC grew its stake in shares of Greenbrook TMS by 80.0% in the 3rd quarter. Masters Capital Management LLC now owns 450,000 shares of the company’s stock valued at $ 3,339,000 after buying an additional 200,000 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Greenbrook TMS in the 4th quarter valued at approximately $ 288,000. Institutional investors own 16.73% of the company’s stock.

Shares of GBNH stock opened at $ 2.28 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 2.26. Greenbrook TMS has a 12-month low of $ 2.01 and a 12-month high of $ 13.89. The business’s fifty day simple moving average is $ 2.89 and its 200-day simple moving average is $ 4.16.

About Greenbrook TMS (Get Rating)

Greenbrook TMS Inc, together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services.

Further Reading

Get a free copy of the Zacks research report on Greenbrook TMS (GBNH)

For more information about research offers from Zacks Investment Research, visit

Receive News & Ratings for Greenbrook TMS Daily – Enter your email address below to receive a concise daily summary of the latest news and analyzes’ ratings for Greenbrook TMS and related companies with’s FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker